Lilly’s Bamlanivimab (LY-CoV555) Receives FDA Emergency

New Post Public Reply Private Reply Replies (0) Message Board
Mo
691
Lilly’s Bamlanivimab (LY-CoV555) Receives FDA Emergency Use Authorization: A First COVID-19 Patients at High Risk
NOV 11, 2020 | COVID-19, EMERGENCY USE AUTHORIZATION, FDA, LY-COV555, MONOCLONAL ANTIBODY, NEWS

Lilly’s Bamlanivimab (LY-CoV555) Receives FDA Emergency Use Authorization A First COVID-19 Patients at High Risk

The U.S. Food and Drug Administration (FDA) today granted the first Emergency Use Authorization (EUA) for a monoclonal antibody targeting SARS-CoV-2, the virus behind COVID-19. Namely, bamlanivimab (LY-CoV555), an investigational neutralizing antibody developed by Eli Lilly and Company’s (NYSE: LLY) is now authorized for the treatment of mild to moderate COVID-19 in adults and pediatric patients 12 years and older with a positive COVID-19 test, who are at high risk for progressing to severe COVID-19 and/or hospitalization. Bamlanivimab should be administered as soon as possible after a positive COVID-19 test and within 10 days of symptom onset. The authorization allows for the distribution and emergency use of bamlanivimab, which is administered via a single intravenous infusion. Lilly has smartly tested this investigational product for those at high risk at early onset of the infection. Importantly, an EUA doesn’t mean an approval. Lilly doesn’t know if this drug is ultimately safe and effective for treatment of COVID-19: its still an investigational product. Based on a previous TrialSite report, this authorization triggers a deal worth up to $12.5 billion for Eli Lilly. TrialSite posits that National Institutes of Health should still be investigating low cost, effective treatments, especially for those high risk patients recently diagnosed with COVID-19.

TrialSite News offers a brief breakdown of this latest FDA action.

Why is this a breakthrough EUA?

Because there has been absolutely no FDA authorized (whether formally registered or EUA) treatment for early stage onset of COVID-19. To date, when an individual tests positive for COVID-19 but has mild to moderate symptoms they are typically sent home and told to rest and monitor the condition. This unfortunately is problematic according to many physicians. Now there is an emergency authorized treatment for this early stage in those that are considered high risk. It’s important to note however that Lilly explicitly reminds that bamlanivimab is still investigational, meaning they don’t know if it treats COVID-19 effectively and safely. See the FDA’s letter here.

Daniel Skovronsky, M.D., Ph.D., Lilly’s chief scientific officer and president of Lilly Research Laboratories commented on the action “The BLAZE-1 data show bamlanivimab, when given early in the disease course, may help patients clear the virus and reduce COVID-related hospitalizations, supporting our belief that neutralizing antibodies can be an important therapeutic option for patients fighting this virus.” The Lilly executive continued “We’re proud of the speed with which we have been able to bring patients this therapy specifically designed to treat COVID-19. We thank those who have contributed to this medical advancement, particularly the clinical trial investigators and participants around the country.”

Who benefits from this EUA?

Potentially those individuals that have been diagnosed with SARS-CoV-2 that are deemed high risk, for example the elderly, or someone with obesity issues, or other comorbidities. Their physicians can now potentially administer this powerful monoclonal antibody therapy.

What is the basis for the EUA?

The BLAZE-1 clinical trial paved the way for this EUA. The randomized, double-blind, placebo-controlled Phase 2 study in patients with recently diagnosed mild to moderate COVID-19 in the outpatient setting. Patients treated with bamlanivimab showed reduced viral load and rates of symptoms and hospitalization.

In BLAZE-1, frequency and types of adverse events were similar between bamlanivimab and placebo, with the majority being mild to moderate in severity. Infusion reactions and other allergic hypersensitivity events have been reported. The EUA includes a warning for hypersensitivity including anaphylaxis and infusion-related reactions.

Is the EUA the same as an FDA Approval?

No. Bamlanivimab has not been approved by the FDA for any use. It is not known if bamlanivimab is safe and effective for the treatment of COVID-19.

Bamlanivimab is authorized under an Emergency Use Authorization only for the duration of the declaration that circumstances exist justifying the authorization of the emergency use of bamlanivimab under Section 564(b)(1) of the Act, 21 U.S.C § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.

The FDA grants emergency use authorization to provide availability of a medicine that may help diagnose, treat or prevent a life-threatening disease when no adequate and approved alternatives are available.

This use of bamlanivimab is authorized only for the duration of the declaration that circumstances exist justifying the authorization of the emergency use, unless the authorization is terminated or revoked sooner. The authorization is temporary and does not replace the formal review and approval process. Bamlanivimab remains an investigational drug and has not been approved under a Biologics License Application (BLA). Evaluation of its safety and efficacy is ongoing across a range of patient populations impacted by COVID-19. Data from these studies will be used to support a future BLA submission involving bamlanivimab.

What are the logistics of the EUA? How does it work?

Lilly is now authorized under this EUA to manufacture the investigational product specifically for the purposes of treating individuals considered high risk who have been recently diagnosed with COVID-19. Now doctors will have access to this investigational therapy.

Lilly will begin shipping bamlanivimab immediately to AmerisourceBergen, a national distributor, which will distribute it as directed by the U.S. government’s allocation program. For the most up-to-date information regarding access to bamlanivimab, Lilly suggests in their press release that patients should speak with their health care providers, and health care providers should contact their state health department directly.

What is the cost of this drug?

Lilly has pointed out in their press release that the U.S. government has purchased 300,000 doses of bamlanivimab and committed that Americans will have no out-of-pocket costs for the medicine, although healthcare facilities may charge a fee for the product’s administration.

TrialSite already reported that this totaled $12.5 billion—an unprecedented drug deal. Of course, this cost is ultimately absorbed by the taxpayer and additional health provider fees may add up to a substantial amount. TrialSite will be monitoring this carefully.

Will the federal government be responsible for the allocation of this investigational drug?

Yes. The federal government is responsible for the appropriate allocation of bamlanivimab. Weekly allocation decisions will be proportionally based on confirmed COVID-19 cases in each state and territory over the previous seven days, based on data from the U.S. Department of Health and Human Services’ Protect data collection platform. Each week, state and territorial health departments will select sites of care (that are accessible and can minimize infection transmission) to receive allocated doses and will provide AmerisourceBergen the list of sites. Sites of care will then confirm their need and AmerisourceBergen will distribute bamlanivimab overnight.

What is the manufacturing effort involved?

Lilly has been making considerable investments in manufacturing capacity at risk. This is one reason why they have pegged product price at $12,500 per dose for the EUA. Lilly sought, again at risk, that the product production could be ready for rapid access of this treatment to patients around the world. Lilly reminds all in their recent press release that they have maintained a robust, global supply chain in place to produce bamlanivimab, with numerous manufacturing sites worldwide.

Lilly anticipates manufacturing up to one million doses of bamlanivimab 700 mg by the end of 2020, for use around the world through early next year. Beginning in Q1 2021, the supply of Lilly’s antibody therapy is expected to increase substantially, as additional manufacturing resources come online throughout the year.

Is the product authorized on an emergency basis anywhere else?

No not yet. However, the Indianapolis-based pharmaceutical company is in discussions with global regulators to make bamlanivimab available around the world. Global allocation will be made based on Lilly’s guiding principles that aim to ensure access for patients with high unmet needs, no matter where they live.

About the Investigational Product

Bamlanivimab is a recombinant, neutralizing human IgG1 monoclonal antibody (mAb) directed against the spike protein of SARS-CoV-2. It is designed to block viral attachment and entry into human cells, thus neutralizing the virus, potentially treating COVID-19. Bamlanivimab emerged from the collaboration between Lilly and AbCellera to create antibody therapies for the prevention and treatment of COVID-19. Lilly scientists rapidly developed the antibody in less than three months after it was discovered by AbCellera (University of British Columbia spinoff) and the scientists at the National Institute of Allergy and Infectious Diseases (NIAID) Vaccine Research Center. It was identified from a blood sample taken from one of the first U.S. patients who recovered from COVID-19.

Lilly has successfully completed a Phase 1 study of bamlanivimab in hospitalized patients with COVID-19 (NCT04411628). A Phase 2 study in people recently diagnosed with COVID-19 in the ambulatory setting (BLAZE-1, NCT04427501) is ongoing. A Phase 3 study of bamlanivimab for the prevention of COVID-19 in residents and staff at long-term care facilities (BLAZE-2, NCT04497987) is also ongoing. In addition, bamlanivimab is being tested in the National Institutes of Health-led ACTIV-2 study in ambulatory COVID-19 patients.

Are there risks with this investigational product?

Absolutely. There is very limited amounts of clinical data and serious and unexpected adverse events may occur that have not been previously reported with use of bamlanivimab. Risks include hypersensitivity including anaphylaxis and infusion-related reactions. Moreover, one of the clinical trials involving this investigational product was paused. Moreover the drug poses potential greater risk to hospitalized patients. See FDA letter for more details.

Call to Action: See Lilly’s press release as well as FDA letter. For those seeking more information about bamlanivimab in COVID-19, contact Lilly’s 24-hour support line at 1-855-LillyC19 (1-855-545-5921).
Scroll down for more posts ▼

Top 10 Most Recent News Articles

DKSH's Vietnam Oncology Pact Carries Real Promise, Risk

Updated Category News Views 186

A cancer-market announcement ought to make investors pause before they reach for a spreadsheet. Specialised Therapeutics and DKSH have signed an exclusive partnership to bring oncology therapies into Vietnam, and the human case is painfully clear: the country recorded an estimated 180,000 new cancer cases and more than 120,000 deaths annually in the 2022 GLOBOCAN data....

Continue Reading
Mission Inn’s Lights Enter a Tender New Ownership Era

Updated Category News Views 775

A holiday spectacle can outlive the hands that hung its first bulb. Riverside is about to test that truth in public, under millions of tiny lights and the very large shadow of a family departure. The Mission Inn Festival of Lights returns in 2026 without Kelly and Duane Roberts as hotel owners for the first time in more than three decades. Duane Roberts died in 2025, the...

Continue Reading
PHONO's 150 MW RE+ Win Tests Its U.S. Solar Staying Power

Updated Category News Views 570

A trade-show order book is not cash in the bank, but 150 MW is still a number worth circling in red. PHONO used RE+ 2026 in Las Vegas, held November 17 through 19, to celebrate 20 years in business, parade its solar and storage lineup, and announce new U.S. orders. In a solar market that has become touchier about provenance, compliance and delivered economics, the company...

Continue Reading
UAE Trust Model Faces Its Hardest Test During Crisis

Updated Category News Views 414

A country’s reputation is usually invisible right up until the machinery rattles. Then people, investors, trading partners and residents stop listening to polished slogans and start watching whether airports function, services hold up, information arrives, and business can keep moving. That was the useful core of Saeed Al Eter’s remarks at Ajman Media Forum 2026: soft...

Continue Reading
UAE Ties Diplomacy, Media and AI Into a Shared Signal

Updated Category News Views 128

Influence is getting harder to measure, and easier to squander, which is why the message from Ajman deserves more than a polite nod. At the 2026 Ajman Media Forum, THE SIGNAL, Foreign Affairs Undersecretary Omar Obaid Alhesan Alshamsi made the UAE’s position plain: diplomacy and media are no longer separate lanes. Both operate on words, context, trust and the difficult...

Continue Reading
Luca's Campo Morado Denial Makes Guerrero Risk Clear

Updated Category News Views 94

A Dangerous Headline Needs More Than a Quick Rebuttal One ugly allegation can do more damage to a junior miner than a lousy quarter, especially when it involves a mine in Guerrero State and alleged criminal control. Luca Mining has flatly rejected Mexican media reports claiming that its Campo Morado Mine is controlled by a criminal organization. The company says the...

Continue Reading
PettiChat’s Digital Pet Twin Has Real Consumer Pull

Updated Category News Views 502

A Collar Gadget Is Chasing the Empty-House Problem Leave a dog or cat alone for a few hours and plenty of owners turn into amateur detectives. Did the cat eat? Has the dog been pacing? Why was that one weird noise caught on the home camera? Seattle startup PettiChat is trying to turn that itch into a product category with PettiLive!, a screen-based version of a pet that...

Continue Reading
Build-A-Bear Lawsuit Notice Carries a Date Problem

Updated Category News Views 179

Something is badly out of sequence in the Build-A-Bear shareholder alert, and that matters before anybody gets carried away by the legal boilerplate. The notice says investors who bought NYSE: BBW securities from March 28, 2026 through August 26, 2026 may be covered by a proposed federal securities class action. It also says the lead-plaintiff deadline is January 19,...

Continue Reading
Australia Leads TTW's 2027 Global Travel Country List

Updated Category News Views 106

A travel ranking is a map, not a balance sheet, and that distinction matters more than the glossy numbering. TTW has put Australia at the head of its editorial list of the 50 best countries to visit in 2027, followed by Switzerland, Japan, Canada and Thailand. Fair enough. Those are formidable tourism brands with the scenery, infrastructure and cultural pull to back up...

Continue Reading
Global Child Tests Purpose Travel's Expanding Media Reach

Updated Category News Views 114

Celebrity travel programming usually melts into the wallpaper, but Global Child is trying to make the scenery answer for itself. Its new season of Global Child “Travel & Purpose” puts Andrea Bocelli in Tuscany, Isabela Merced in Peru and John Malkovich in Croatia, while tying each destination to a broader local-good mission. That is a more thoughtful pitch than...

Continue Reading

Top 5 Most Recently Viewed Articles

Aitech Honored for Its Breakthrough in Rugged AI Technology

Updated Category News Views 382

Aitech Secures 2025 Artificial Intelligence Excellence Award Aitech, renowned for its rugged embedded systems tailored for military, aerospace, and space applications, has recently been distinguished as a winner in the 2025 Artificial Intelligence Excellence Awards organized by the Business Intelligence Group. This accolade celebrates the innovative strides in AI and...

Continue Reading
National Hydropower Association Emphasizes Hydropower's Importance

Updated Category News Views 129

National Hydropower Association Celebrates Hydropower Day The National Hydropower Association (NHA), the foremost trade association for the water power industry in the U.S., is excited to celebrate National Hydropower Day. This annual event pays tribute to the water power sector and the dedicated American workers who contribute to this essential renewable resource. The...

Continue Reading
Changing Perspectives: German Parents Embrace Cannabis Cultivation

Updated Category News Views 269

Changing Perspectives on Cannabis in Germany In Germany, the landscape of cannabis use has transformed remarkably in the past year. With the legislation on cannabis legalization now in effect, the cultural and social dynamics are evolving. Although there are mixed feelings on the topic, it's evident that younger people, particularly parents, are leaning towards supporting...

Continue Reading
Select Water Solutions Unveils 2025 Q1 Earnings Event Details

Updated Category News Views 257

Select Water Solutions Announces 2025 First Quarter Earnings Select Water Solutions, Inc. (NYSE: WTTR) is gearing up for the announcement of its financial performance for the first quarter of 2025. The company has confirmed the release date of these results, which is set to take place after the market closes on an upcoming Tuesday. This is an exciting time for investors...

Continue Reading
Colabor Group's Strategic Moves Shape Future Financial Outlook

Updated Category News Views 183

Colabor Group's Financial Performance Overview Colabor Group Inc. (TSX: GCL) reveals its financial results for the fourth quarter and fiscal year, providing insights into its ongoing market performance. Fourth Quarter Highlights In the fourth quarter, Colabor Group demonstrated resilience with a sales increase of 3.2%, reaching $202.6 million. Comparatively, sales were at...

Continue Reading